|
1
|
Motzer RJ, Bander NH and Nanus DM:
Renal-cell carcinoma. N Engl J Med. 335:865–875. 1996. View Article : Google Scholar
|
|
2
|
Costa LJ and Drabkin HA: Renal cell
carcinoma: new developments in molecular biology and potential for
targeted therapies. Oncologist. 12:1404–1415. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Mickisch GH: Gene therapy on renal-cell
carcinoma: magic bullet or tragic insanity? World J Urol.
13:178–185. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Chen XL, Cao LQ, She MR, Wang Q, Huang XH
and Fu XH: Gli-1 siRNA induced apoptosis in Huh7 cells. World J
Gastroenterol. 14:582–589. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Jin KL, Park JY, Noh EJ, et al: The effect
of combined treatment with cisplatin and histone deacetylase
inhibitors on HeLa cells. J Gynecol Oncol. 21:262–268. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Motzer RJ and Russo P: Systemic therapy
for renal cell carcinoma. J Urol. 163:408–417. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Aso Y, Tazaki H, Umeda T and Marumo K:
Treatment of renal cell carcinoma with systemic administration of
intermediate doses of recombinant human interleukin-2 alone.
Recombinant Human Interleukin-2 (S-6820) Research Group on Renal
Cell Carcinoma. Prog Clin Biol Res. 303:681–688. 1989.
|
|
8
|
Hayashi T, Miyagawa Y, Tsujimura A,
Nonomura N, Minami M and Okuyama A: A case of renal cell carcinoma
with multiple lung metastases refractory to interferon-α showing
complete remission by interleukin-2 monotherapy. Int J Urol.
13:805–808. 2006.PubMed/NCBI
|
|
9
|
Logan JE, Rampersaud EN, Sonn GA, et al:
Systemic therapy for metastatic renal cell carcinoma: a review and
update. Rev Urol. 14:65–78. 2012.PubMed/NCBI
|
|
10
|
Yamamoto Y, Fujita M, Koma H, et al:
15-Deoxy-Δ12,14-prostaglandin J2enhanced the
anti-tumor activity of camptothecin against renal cell carcinoma
independently of topoisomerase-II and PPARγ pathways. Biochem
Biophys Res Commun. 410:563–567. 2011.
|
|
11
|
Inoue K, Kawahito Y, Tsubouchi Y, et al:
Expression of peroxisome proliferator-activated receptor gamma in
renal cell carcinoma and growth inhibition by its agonists. Biochem
Biophys Res Commun. 287:727–732. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Ward JE, Gould H, Harris T, Bonacci JV and
Stewart AG: PPARγ ligands, 15-deoxy-Δ12,14-prostaglandin
J2and rosiglitazone regulate human cultured airway
smooth muscle proliferation through different mechanisms. Br J
Pharmacol. 141:517–525. 2004.
|
|
13
|
Suzuki K and Uyeda M: Inhibitory
properties of antitumor prostaglandins against topoisomerases.
Biosci Biotechnol Biochem. 66:1706–1712. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Yagami T, Ueda K, Asakura K, et al: Novel
binding sites of 15-deoxy-Δ12,14-prostaglandin
J2in plasma membranes from primary rat cortical neurons.
Exp Cell Res. 291:212–227. 2003.
|
|
15
|
Yamamoto Y, Takase K, Kishino J, et al:
Proteomic identification of protein targets for
15-deoxy-Δ12,14-prostaglandin J2in neuronal
plasma membrane. PLoS One. 6:e175522011.
|
|
16
|
Zhang YQ, Tang XQ, Sun L, et al:
Rosiglitazone enhances fluorouracil-induced apoptosis of HT-29
cells by activating peroxisome proliferator-activated receptor γ.
World J Gastroenterol. 13:1534–1540. 2007.PubMed/NCBI
|
|
17
|
Hamaguchi N, Hamada H, Miyoshi S, et al:
In vitro and in vivo therapeutic efficacy of the PPARγ agonist
troglitazone in combination with cisplatin against malignant
pleural mesothelioma cell growth. Cancer Sci. 101:1955–1964.
2010.
|
|
18
|
Tikoo K, Kumar P and Gupta J:
Rosiglitazone synergizes anticancer activity of cisplatin and
reduces its nephrotoxicity in 7,12-dimethyl benz{a}anthracene
(DMBA) induced breast cancer rats. BMC Cancer. 9:1072009.PubMed/NCBI
|
|
19
|
Kanbe E, Abe A, Towatari M, Kawabe T,
Saito H and Emi N: DR1-like element in human topoisomerase IIα gene
involved in enhancement of etoposide-induced apoptosis by PPARγ
ligand. Exp Hematol. 31:300–308. 2003.PubMed/NCBI
|
|
20
|
Yuan J, Takahashi A, Masumori N, et al:
Ligands for peroxisome proliferator-activated receptor gamma have
potent antitumor effect against human renal cell carcinoma.
Urology. 65:594–599. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Yoshimura R, Matsuyama M, Hase T, et al:
The effect of peroxisome proliferator-activated receptor-γ ligand
on urological cancer cells. Int J Mol Med. 12:861–865. 2003.
|
|
22
|
Khelifa T and Beck WT: Merbarone, a
catalytic inhibitor of DNA topoisomerase II, induces apoptosis in
CEM cells through activation of ICE/CED-3-like protease. Mol
Pharmacol. 55:548–556. 1999.PubMed/NCBI
|
|
23
|
Brockman JA, Gupta RA and Dubois RN:
Activation of PPARγ leads to inhibition of anchorage-independent
growth of human colorectal cancer cells. Gastroenterology.
115:1049–1055. 1998.
|
|
24
|
Chen YX, Zhong XY, Qin YF, Bing W and He
LZ: 15d-PGJ2inhibits cell growth and induces apoptosis
of MCG-803 human gastric cancer cell line. World J Gastroenterol.
9:2149–2153. 2003.
|
|
25
|
Clay CE, Atsumi GI, High KP and Chilton
FH: Early de novo gene expression is required for
15-deoxy-Δ12,14-prostaglandin J2-induced
apoptosis in breast cancer cells. J Biol Chem. 276:47131–47135.
2001.
|
|
26
|
Li L, Tao J, Davaille J, et al:
15-deoxy-Δ12,14-prostaglandin J2induces
apoptosis of human hepatic myofibroblasts. A pathway involving
oxidative stress independently of peroxisome-proliferator-activated
receptors. J Biol Chem. 276:38152–38158. 2001.
|
|
27
|
McClay EF, Winski PJ, Jones JA, Jennerette
J III and Gattoni-Celli S:
Δ12-Prostaglandin-J2is cytotoxic in human
malignancies and synergizes with both cisplatin and radiation.
Cancer Res. 56:3866–3869. 1996.
|
|
28
|
Huang X, Okafuji M, Traganos F, Luther E,
Holden E and Darzynkiewicz Z: Assessment of histone H2AX
phosphorylation induced by DNA topoisomerase I and II inhibitors
topotecan and mitoxantrone and by the DNA cross-linking agent
cisplatin. Cytometry A. 58:99–110. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Aldini G, Carini M, Vistoli G, et al:
Identification of actin as a
15-deoxy-Δ12,14-prostaglandin J2target in
neuroblastoma cells: mass spectrometric, computational, and
functional approaches to investigate the effect on cytoskeletal
derangement. Biochemistry. 46:2707–2718. 2007.
|
|
30
|
Mizutani H, Tada-Oikawa S, Hiraku Y,
Oikawa S, Kojima M and Kawanishi S: Mechanism of apoptosis induced
by a new topoisomerase inhibitor through the generation of hydrogen
peroxide. J Biol Chem. 277:30684–30689. 2002. View Article : Google Scholar
|
